Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
44
NVCR Quote, Financials, Valuation and Earnings
Last price:
$13.18
Seasonality move
:
-11.64%
Day range:
$12.80 - $13.97
52-week range:
$10.70 - $32.06
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.31x
P/B ratio:
4.41x
Volume:
1.4M
Avg. volume:
1.9M
1-year change:
-56.36%
Market cap:
$1.5B
Revenue:
$605.2M
EPS (TTM):
-$1.61
Analysts' Opinion
-
Consensus RatingNovoCure Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $24.79, NovoCure Ltd. has an estimated upside of 84.42% from its current price of $13.44.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $13.50 representing 100% downside risk from its current price of $13.44.
Fair Value
-
According to the consensus of 6 analysts, NovoCure Ltd. has 84.42% upside to fair value with a price target of $24.79 per share.
NVCR vs. S&P 500
-
Over the past 5 trading days, NovoCure Ltd. has overperformed the S&P 500 by 1.26% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
NovoCure Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
NovoCure Ltd. has grown year-over-year revenues for 8 quarters straight. In the most recent quarter NovoCure Ltd. reported revenues of $167.2M.
Earnings Growth
-
NovoCure Ltd. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter NovoCure Ltd. reported earnings per share of -$0.33.
Enterprise value:
1.3B
EV / Invested capital:
1.11x
Price / LTM sales:
2.31x
EV / EBIT:
--
EV / Revenue:
1.97x
PEG ratio (5yr expected):
-0.53x
EV / Free cash flow:
-19.44x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$485M
Return On Assets:
-14.06%
Net Income Margin (TTM):
-27.66%
Return On Equity:
-50.08%
Return On Invested Capital:
-16.67%
Operating Margin:
-21.54%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $504M | $577.7M | $642.3M | $155.1M | $167.2M | |
| Gross Profit | $379.4M | $442.3M | $485M | $119.7M | $122.5M | |
| Operating Income | -$224.1M | -$150.2M | -$175.8M | -$32.1M | -$36M | |
| EBITDA | -$213.2M | -$139.3M | -$162.2M | -$29.6M | -$32.4M | |
| Diluted EPS | -$1.86 | -$1.39 | -$1.61 | -$0.28 | -$0.33 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.1B | $1.1B | $1B | $1.1B | $1.2B | |
| Total Assets | $1.1B | $1.2B | $1.1B | $1.2B | $1.4B | |
| Current Liabilities | $124.5M | $141.1M | $157.2M | $735M | $776M | |
| Total Liabilities | $707.3M | $728.8M | $752.6M | $861.2M | $1B | |
| Total Equity | $413.2M | $445.4M | $393.7M | $360.8M | $341.3M | |
| Total Debt | $572.9M | $579.5M | $590M | $675.6M | $797.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$62.5M | -$37.5M | -$34.5M | $10.4M | $20.6M | |
| Cash From Investing | -$42.4M | -$19.5M | $78.7M | $10.2M | $71.4M | |
| Cash From Financing | $17.3M | $89.5M | $110.8M | $100K | $100.5M | |
| Free Cash Flow | -$89.2M | -$78.2M | -$65.2M | -$307K | $14.9M | |
NVCR
Sector
Market Cap
$1.5B
$28.4M
Price % of 52-Week High
41.93%
51.17%
Dividend Yield
0%
0%
Shareholder Yield
-2.45%
-1.49%
1-Year Price Total Return
-56.36%
-16.67%
Beta (5-Year)
0.825
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$13.01
200-day SMA
Sell
Level
$14.94
Bollinger Bands (100)
Buy
Level
11.58 - 13.48
Chaikin Money Flow
Sell
Level
-21.3M
20-day SMA
Buy
Level
$12.55
Relative Strength Index (RSI14)
Buy
Level
59.21
ADX Line
Buy
Level
14.74
Williams %R
Sell
Level
-17.4342
50-day SMA
Buy
Level
$12.57
MACD (12, 26)
Buy
Level
0.21
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
76.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.282)
Sell
CA Score
(Annual)
Level (-1.8048)
Buy
Beneish M-Score
(Annual)
Level (-2.8421)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (2.1903)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Stock Forecast FAQ
In the current month, NVCR has received 4 Buy ratings 2 Hold ratings, and 0 Sell ratings. The NVCR average analyst price target in the past 3 months is $24.79.
-
Where Will NovoCure Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that NovoCure Ltd. share price will rise to $24.79 per share over the next 12 months.
-
What Do Analysts Say About NovoCure Ltd.?
Analysts are divided on their view about NovoCure Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that NovoCure Ltd. is a Sell and believe this share price will drop from its current level to $13.50.
-
What Is NovoCure Ltd.'s Price Target?
The price target for NovoCure Ltd. over the next 1-year time period is forecast to be $24.79 according to 6 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is NVCR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for NovoCure Ltd. is a Buy. 4 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NVCR?
You can purchase shares of NovoCure Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase NovoCure Ltd. shares.
-
What Is The NovoCure Ltd. Share Price Today?
NovoCure Ltd. was last trading at $13.18 per share. This represents the most recent stock quote for NovoCure Ltd.. Yesterday, NovoCure Ltd. closed at $13.44 per share.
-
How To Buy NovoCure Ltd. Stock Online?
In order to purchase NovoCure Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get NVCR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NVCR
Sector
P/E ratio
--
23.89x
PEG ratio
-0.53x
-0.01x
P/B ratio
4.41x
1.81x
Price / LTM sales
2.31x
1.58x
Growth Metrics
NVCR
Sector
Revenue growth
7.81%
4.62%
Earnings growth
-17.92%
10.7%
Revenue (5-year growth)
11.49%
6.5%
Earnings forecast
-$0.42
-$0.21
Profitability
NVCR
Sector
Profitability FY 2024
$469M
$3.6M
Return on invested capital
-16.67%
-31.84%
Return on assets
-14.06%
-27.96%
Return on equity
-50.08%
-37.63%
Earnings Date
Last Earnings Date
Oct
30
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Jan
29
Balance Sheet
NVCR
Sector
Total cash
$1B
$26.4M
Short term investments
$796.1M
$25.7M
Total assets
$1.2B
$76.9M
Long term debt
$797.9M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 4.51% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is up 0.04% over the past day.
Buy
60
ZBIO alert for Dec 23
Zenas BioPharma, Inc. [ZBIO] is down 0.54% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
